Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis
- 276 Downloads
Polymorphisms in interleukin (IL)-4/IL-13 pathway genes have previously been reported to be associated with glioma susceptibility, although results are inconsistent. We therefore performed an updated meta-analysis to determine a more precise estimation of this relationship. Twelve eligible studies were identified by searching PubMed, EMBASE, Web of Science, and the Cochrane Library electronic databases. Nine polymorphisms in genes within the IL-4/IL-13 pathway (IL-4 rs2243250, rs2070874, rs2243248, IL-4R rs1805011, rs1805012, rs1805015, rs1801275, and IL-13 rs20541 and rs1800925) were assessed for their relationship with glioma risk by computing odds ratios (ORs) and corresponding 95 % confidence intervals (CIs). Akaike’s information criterion (AIC) was used to identify the best genetic model for each polymorphism. No association between IL-4/IL-13 pathway genetic polymorphisms and glioma risk was observed in the overall population, although a significant association was found between rs2234248 and glioblastoma when stratified by histological subtype (log-additive model, OR 1.57, 95 % CI 1.11–2.24). This meta-analysis therefore suggested that IL-4/IL-13 pathway genetic polymorphisms are not associated with glioma risk.
KeywordsGlioma Meta-analysis Interleukin-4 Interleukin-4R Interleukin-13 Single nucleotide polymorphism
We thank Dr. Melissa L. Bondy from the Texas MD Anderson Cancer Center and Dr. Kyle M. Walsh from the Helen Diller Family Comprehensive Cancer Center for generously providing their data.
Conflicts of interest
- 8.Schlehofer B, Siegmund B, Linseisen J, Schuz J, Rohrmann S, Becker S, et al. Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy. 2011;66(11):1434–41. doi: 10.1111/j.1398-9995.2011.02670.x.CrossRefPubMedGoogle Scholar
- 12.Liu H, Jacobs BS, Liu J, Prayson RA, Estes ML, Barnett GH, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother. 2000;49(6):319–24. doi: 10.1007/s002620000110.CrossRefPubMedGoogle Scholar
- 17.Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, et al. An international case–control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2448–54. doi: 10.1158/1055-9965.EPI-07-0480.CrossRefPubMedGoogle Scholar
- 22.Walsh KM, Anderson E, Hansen HM, Decker PA, Kosel ML, Kollmeyer T, et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol. 2013;37(2):222–8. doi: 10.1002/gepi.21707.CrossRefPubMedGoogle Scholar
- 24.Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, Al-Madhani A, Ganguly SS, et al. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric Cancer. 2006;9(4):284–90. doi: 10.1007/s10120-006-0392-5.CrossRefPubMedGoogle Scholar
- 37.Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer. 1999;82(2):155–60. doi: 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P.CrossRefPubMedGoogle Scholar